Patents Examined by Sarvamangala Devi
  • Patent number: 11576939
    Abstract: The present invention discloses a method for preserving a probiotic composition, including: providing a bacterial cell suspension, which is one or more bacterial cell suspensions of a bacterium or Saccharomyces boulardii; mixing the bacterial cell suspension with a sodium alginate solution or an alginic acid solution; and adding the mixture to a calcium ion solution until the mixture is immobilized in a shape. The technology of the present invention has the effects of long-term preservation at room temperature and resistance to high temperature, and can be applied to ordinary bacterial strains, without being limited to a small number of bacterial species able to form endospore, and without requiring the strains to be frozen for preservation. The method of the present invention can be applied to the preparation of aquatic feeds, animal feeds, or probiotics that human beings need.
    Type: Grant
    Filed: July 16, 2020
    Date of Patent: February 14, 2023
    Inventors: Ying-Tang Huang, Ling-Hong Zheng
  • Patent number: 11530433
    Abstract: Provided herein, in some embodiments, are artificial secretion peptides capable of directing secretion from Lactobacillus for use, for example, in producing heterologous proteins, including therapeutic proteins.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: December 20, 2022
    Assignee: President and Fellows of Harvard College
    Inventors: Anik Debnath, George Church
  • Patent number: 11529406
    Abstract: The present invention relates to Siphoviridae bacteriophage Clo-PEP-2 (accession number KCTC 13185BP), separated from nature, which is capable of killing Clostridium perfringens and has a genome expressed by sequence number 1 and a method for preventing or treating diseases, induced by Clostridium perfringens, by means of a composition comprising the Siphoviridae bacteriophage Clo-PEP-2 as an active ingredient.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: December 20, 2022
    Inventors: Seong Jun Yoon, Soo Youn Jun, Hyoun Rok Paik, Jee Soo Son, Hee Jeong Shin, Sang Hyeon Kang
  • Patent number: 11506661
    Abstract: The present invention relates to detecting serum anti-FadA antibodies in test samples from a patient. Additionally, aspects of the present invention provide the basis for detection of serum anti-FadA antibody levels from test samples and correlation with various conditions of clinical relevance.
    Type: Grant
    Filed: May 3, 2018
    Date of Patent: November 22, 2022
    Assignee: The Trustees of Columbia University In the City of New York
    Inventor: Yiping Han
  • Patent number: 11492589
    Abstract: The present disclosure relates to a novel Lactobacillus plantarum CJLP475 strain having acid-resistance, bile-resistance and an immune-enhancing activity, and a composition including the same.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: November 8, 2022
    Inventors: Min-Jeong Kim, Hee-Yeon Kim, Ho Jin Moon, Seo Hyung Woo, Kyung Min Lee, Yoon Tack Jang, Bong Joon Kim, Sung Hun Kim
  • Patent number: 11491220
    Abstract: Methods of producing bioconjugates of O-antigen polysaccharides covalently linked to a carrier protein using recombinant host cells are provided. The recombinant host cells used in the methods described herein encode a particular oligosaccharyl transferase enzyme depending on the O-antigen polysaccharide bioconjugate to be produced. The oligosaccharyl transferase enzymes can be PglB oligosaccharyl transferase or variants thereof. Also provided are compositions containing the bioconjugates, and methods of using the bioconjugates and compositions described herein to vaccinate a subject against extra-intestinal pathogenic E. coli. (ExPEC).
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: November 8, 2022
    Assignees: Janssen Pharmaceuticals, Inc.
    Inventors: Jeroen Geurtsen, Pieter Jan Burghout, Eveline Marleen Weerdenburg, Jan Theunis Poolman, Kellen Cristhina Fae, Patricia Ibarra Yon, Darren Robert Abbanat, Stefan Jochen Kemmler, Michael Thomas Kowarik, Manuela Mally, Veronica Gambillara Fonck, Martin Edward Braun, Maria Paula Carranza Sandmeier
  • Patent number: 11492588
    Abstract: The disclosure discloses Lactococcus lactis subsp. lactis CCFM1018 and application thereof in preparation of food and medicine for excreting a plasticizer, and belongs to the technical field of microorganisms. The Lactococcus lactis subsp. lactis CCFM1018 not only is significantly better than the intestinal resident bacteria Escherichia coli and Enterococcus faecalis in terms of the effect of promoting the excretion of DEHP and MEHP, but also is better than the commercial strain Lactobacillus rhamnosus LGG. Therefore, the Lactococcus lactis subsp. lactis CCFM1018 of the disclosure can be used as an effective means to prevent and alleviate body damage caused by DEHP and MEHP, and does not have toxic or side effects of drugs. Lactococcus lactis subsp. lactis CCFM1018 can be used to prepare pharmaceutical compositions and fermented food for alleviating and preventing the toxicity of DEHP and metabolites thereof, and has a very broad application prospect.
    Type: Grant
    Filed: September 14, 2020
    Date of Patent: November 8, 2022
    Assignee: Jiangnan University
    Inventors: Gang Wang, Wei Chen, Qian Chen, Jianxin Zhao, Hao Zhang
  • Patent number: 11484584
    Abstract: The present invention relates to an immunogenic complex comprising an amino acid sequence having at least 80% sequence identity with the amino acid sequence of the N-terminal region of a group B Streptococcus surface protein, and a capsular polysaccharide. The immunogenic complex is capable of eliciting protective immunity against group B Streptococcus. The invention further pertains to an immunogenic product comprising the immunogenic complex and an immunogenic fusion protein, the vaccine, the immunogenic complex, or the immunogenic product for use in a method of preventing or treating a group B Streptococcus infection, as well as a method of preventing or treating a group B Streptococcus infection.
    Type: Grant
    Filed: December 10, 2020
    Date of Patent: November 1, 2022
    Inventor: Per Bo Pedersen Fischer
  • Patent number: 11464845
    Abstract: Immunogenic compositions are disclosed that include Neisseria meningitidis microvesicles, such as outer membrane vesicles (OMV) and/or blebs, from PorA?PorB? Neisseria, such as PorA?PorB?RmpM? Neisseria meningitidis. These immunogenic compositions are of use to induce an immune response to Neisseria, including Neisseria meningitidis and Neisseria gonorrhea.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: October 11, 2022
    Assignee: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Margaret Bash, Kathryn Matthias
  • Patent number: 11466074
    Abstract: The invention provides for an isolated antibody that specifically recognizes a galactan-III epitope of the lipopolysaccharide (LPS) O-antigen structure of Klebsiella pneumoniae, which epitope is incorporated in galactan-III repeating units, wherein the galactan-III repeating unit is a branched galactose homopolymer of Formula (I). The invention further provides for a pharmaceutical or diagnostic preparation comprising said antibody, and a method of producing said antibody.
    Type: Grant
    Filed: November 3, 2015
    Date of Patent: October 11, 2022
    Inventors: Valeria Szijarto, Gábor Nagy, Luis Guachalla, Zehra Visram, Eszter Nagy, Jolanta Katarzyna Lukasiewicz
  • Patent number: 11452769
    Abstract: The invention provides compositions and methods for preventing and treating infection by Plasmodium sporozoites.
    Type: Grant
    Filed: January 26, 2016
    Date of Patent: September 27, 2022
    Assignee: Yale University
    Inventors: Erol Fikrig, Yang Zhao
  • Patent number: 11448656
    Abstract: The present invention concerns a composition comprising at least three peptides derived from Mycobacterium tuberculosis antigen Rv2626c, its use in the diagnostic of latently infected Mycobacterium tuberculosis (LTBI) subjects, corresponding methods of use and kits.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: September 20, 2022
    Inventors: Juan Iovanna, Virginia Pasquinelli, Maria Madgalena Gherardi, Hector Eduardo Chuluyan, Ana Inès Rovetta, Delfina Pena, Véronica Edith Garcia
  • Patent number: 11447741
    Abstract: A novel Lactobacillus plantarum strain ATG-K2, ATG-K6 or ATG-K8 and a composition for the prevention or treatment of vaginitis containing the same are proposed. The Lactobacillus plantarum strain ATG-K2, ATG-K6 or ATG-K8 has excellent antimicrobial effects against various pathogenic strains as well as Candida albicans and Gardnerella vaginalis, which are vaginitis pathogens, and thus can be easily used as a composition for the treatment of bacterial vaginosis, vaginal candidiasis, etc., or as a functional health food for the prevention or amelioration of these diseases.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: September 20, 2022
    Assignee: ATOGEN CO., LTD
    Inventors: Bo Ram Beck, Ji Hee Kang, Gun Seok Park, Sung Hoon Im, Do Yeun Jeong, Yong Hyun Lee
  • Patent number: 11439700
    Abstract: Disclosed are methods and compositions related to polypeptides comprising a fusion of the needle tip protein and translocator protein of a type III secretion apparatus (T3SA) from a type III secretion system (T3SS) of a Gram negative bacteria. Disclosed herein are fusion polypeptides comprising a fusion of a needle tip protein, such as, Bsp22, LcrV, BipD, PcrV, CT053, or CT668, or anantigenic fragment thereof; and a translocator protein, such as, BopB, YopB, BipB, PopB, CopB, or CopB2, or anantigenic fragment thereof from a Type III secretion system (T3SS) of a Gram negative bacteria, such as, Bordetella, Burkholderia, Chlamydia, Pseudomonas, Vibrio, or Yersinia.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: September 13, 2022
    Inventors: Wendy L. Picking, William D. Picking
  • Patent number: 11433126
    Abstract: Methods of treating or preventing stress, anxiety, or postoperative cognitive dysfunction. Also provided are methods of improving resilience in a subject by administering a therapeutically effective amount of isolated Mycobacterium.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: September 6, 2022
    Inventors: Christopher A. Lowry, Matthew G. Frank, Laura Fonken, Steven F. Maier
  • Patent number: 11432566
    Abstract: A feed composition for preventing or treating acute hepatopancreatic necrosis disease (AHPND) or white spot syndrome (WSS), having a Bacillus subtilis (KCCM11143P) strain, a Bacillus pumilus (KCCM11144P) strain, and a Bacillus licheniformis (KCCM11270P) strain; culture media thereof; concentrates thereof; or dry matters thereof as an active ingredient. The feed composition exhibits antibacterial activity against Vibrio parahaemolyticus, which causes shrimp AHPND, and antiviral activity against white spot syndrome virus (WSSV), which causes WSS.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: September 6, 2022
    Inventors: Ji Eun Kim, Sung Hun Kim, Jae Won Kim, Seo Hyung Woo, Jongsu Eun, Hayun Jo, Jee Eun Han
  • Patent number: 11427620
    Abstract: It is an object of the present invention to provide a transmission-blocking vaccine using an immunogenic protein which is specifically expressed in the oocyst stage of malaria parasites or a peptide fragment thereof, and an oral transmission-blocking vaccine capable of immunizing various animals involved in the malaria infectious cycle with such a vaccine. The present invention relates to a malaria transmission-blocking vaccine for oral administration containing an immunogenic protein derived from malaria parasite which is specifically expressed in the oocyst stage of malaria parasites or a peptide fragment thereof, and a method of blocking the transmission of malaria using the same.
    Type: Grant
    Filed: September 4, 2017
    Date of Patent: August 30, 2022
    Assignees: Hokusan Co., Ltd., National Institute of Advanced Industrial Science and Technology, School Juridical Person The Kitasato Institute
    Inventors: Noriko Tabayashi, Toru Gotanda, Hanae Sasaki, Noriko Itchoda, Uiko Kagaya, Takeshi Matsumura, Akira Ito, Hiromi Ikadai
  • Patent number: 11421003
    Abstract: Polypeptides comprising a FimH lectin domain comprising an amino acid mutation that causes the FimH lectin domain to be in the low affinity conformation for mannose are described. Pharmaceutical compositions which comprise such polypeptides and methods of stimulating an immune response in a subject in need thereof by administration of the polypeptide are further described.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: August 23, 2022
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: Jan Grijpstra, Marleen Eveline Weerdenburg, Jeroen Geurtsen, Cristhina Kellen Fae, Jakob Louris Feitsma
  • Patent number: 11414464
    Abstract: Disclosed is chimeric polypeptides derived from S. aureus proteins having SEQ ID NOs: 1-9 and 139-146. The chimeric polypeptides are useful as immunogens for providing protective immunity against S. aureus infection. Also disclosed are compositions, methods of treatment and prophylaxis, nucleic acids and vectors comprising the nucleic acids.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: August 16, 2022
    Assignee: Evaxion Biotech A/S
    Inventors: Niels Iversen Møller, Andreas Holm Mattsson, Jens Kringelum
  • Patent number: 11406673
    Abstract: A method of sobering up, comprising administering composition comprising an effective amount of Bacillus coagulans TCI711. The Bacillus coagulans TCI711 is deposited in Consortium Food Industry Research and Development Institute (Deposit number: BCRC910807) and German Microbial and Cell Culture Collection Center (DSMZ-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH) (Deposit number: DSM33163).
    Type: Grant
    Filed: August 14, 2020
    Date of Patent: August 9, 2022
    Assignee: TCI CO., LTD.
    Inventors: Yu-Kai Chiu, Yung-Hsiang Lin